Welcome to our dedicated page for CEL-SCI news (Ticker: CVM), a resource for investors and traders seeking the latest updates and insights on CEL-SCI stock.
CEL-SCI Corporation develops cancer immunotherapy programs centered on Multikine (Leukocyte Interleukin, Injection), an investigational neoadjuvant therapy for squamous cell carcinoma of the head and neck. Company news commonly covers Multikine regulatory interactions, FDA Orphan Drug designation for neoadjuvant use, confirmatory registration-study preparation, and the company's positioning of the therapy before surgery, radiation, and chemotherapy.
Updates also include financial results, public equity offerings used to fund Multikine development, investor presentations, and regional commercialization or regulatory-affairs agreements, including activity in Saudi Arabia. CEL-SCI's disclosures often connect clinical development with working-capital needs and potential international market access.
CEL-SCI (NYSE American:CVM) closed a best-efforts offering of 2,500,000 common shares at $1.00 per share, raising approximately $2.5 million in gross proceeds. Net proceeds are intended for continued development of Multikine, general corporate purposes, and working capital, with ThinkEquity as sole placement agent.
CEL-SCI (NYSE American:CVM) outlined a dual-track strategy for its Multikine immunotherapy in head and neck cancer, combining a U.S. Confirmatory Registration Study expected to start in summer 2026 with a Saudi Arabia regulatory and commercialization partnership.
The 212-patient U.S. trial will target newly diagnosed, locally advanced, resectable head and neck cancer with low PD-L1 expression and no lymph node involvement, the subgroup that in a prior Phase 3 study showed a 73% five-year overall survival rate with Multikine plus standard of care versus 45% with standard of care alone. In Saudi Arabia, partner Amarox will lead local regulatory work, act as exclusive distributor upon approval, and share net revenue 50/50 upon Breakthrough Medicine Designation, with an option to expand distribution across GCC countries.
CEL-SCI (NYSE American:CVM) priced a best-efforts offering of 2,500,000 common shares at $1.00 per share, targeting gross proceeds of $2.5 million. Closing is expected on June 16, 2026, with proceeds for Multikine development, general corporate purposes, and working capital.
CEL-SCI (NYSE American: CVM) will hold a formal signing ceremony with Saudi Amarox at BIO 2026 on June 22, 2026. The event advances their strategic agreement to commercialize and distribute Multikine in Saudi Arabia, with a planned 50%/50% revenue share after Breakthrough Medicine Designation.
Amarox will lead Saudi-FDA interactions and be exclusive distributor upon approval, with an option to expand into GCC countries. The collaboration aligns with Saudi Arabia’s Vision 2030 and growing cancer immunotherapy market, projected to reach $2.7 billion by 2033.
CEL-SCI (NYSE American:CVM) reported fiscal Q2 2026 results and key updates on Multikine. The company is preparing a 212-patient U.S. FDA Confirmatory Registration Study in head and neck cancer, targeting start by summer/fall 2026.
CEL-SCI signed a 50%/50% revenue-sharing partnership with Amarox/b) for Multikine in Saudi Arabia, tied to potential SFDA Breakthrough Medicine Designation, and raised approximately
CEL-SCI (NYSE American: CVM) closed a best-efforts public offering of 6,000,000 common shares at $1.20 per share, generating approximately $7.2 million in gross proceeds.
According to CEL-SCI, net proceeds will fund continued development of Multikine, as well as general corporate purposes and working capital.
CEL-SCI (NYSE American:CVM) priced a best-efforts public offering of 6,000,000 common shares at $1.20 per share, targeting gross proceeds of about $7.2 million. Closing is expected on May 13, 2026, with proceeds funding Multikine development, general corporate purposes, and working capital. ThinkEquity is sole placement agent.
CEL-SCI (NYSE American:CVM) signed a strategic partnership with Amarox for registration, commercialization, and distribution of Multikine for head and neck cancer in Saudi Arabia, with optional GCC expansion.
The agreement includes a 50%/50% net revenue split in Saudi Arabia and exclusive distribution for Amarox upon SFDA approval, targeting SFDA Breakthrough Medicine Designation aligned with Saudi Vision 2030.
CEL-SCI (NYSE American: CVM) reported Q1 FY2026 results and clinical progress for Multikine in head and neck cancer. The company plans to begin enrollment in a 212-patient U.S. confirmatory registration study in summer 2026 and has submitted a Breakthrough Medicine Designation application to the Saudi FDA.
Q1 operating highlights: R&D $3.7M, G&A $1.7M, net loss $5.5M, cash used in operations $4.0M. Prior Phase 3 showed 5-year overall survival 73% vs 45%.
CEL-SCI (NYSE American: CVM) reported fiscal 2025 results and clinical progress for Multikine in head and neck cancer. The company received FDA clearance to proceed with a 212-patient Confirmatory Registration Study with enrollment expected to begin in Spring 2026 and plans to seek early U.S. approval based on pre-surgical response data by 2028. CEL-SCI filed for Breakthrough Medicine Designation in Saudi Arabia and completed manufacturing of Multikine doses for the confirmatory study at its validated U.S. cGMP facility. Fiscal 2025 highlights: R&D $15.9M (-13%), Net loss $25.4M, Operating cash expenditures $17.1M, and Gross proceeds raised $28.3M. The audited financials include an explanatory going concern paragraph.